文献速递其他结缔组织病

抗着丝点抗体阳性的弥漫性皮肤型系统性硬化症患者的表型:一项系统文献综述与荟萃分析

Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2024-12-03

该系统综述与荟萃分析纳入6项观察性研究、共177例抗着丝点抗体阳性弥漫性皮肤型系统性硬化症(ACA-dcSSc)患者,比较其与ACA-lcSSc及ATA-dcSSc的主要器官受累和死亡风险。ACA-dcSSc的间质性肺病(ILD)频率高于ACA-lcSSc(OR 2.60;95%CI 1.39-4.87)但低于ATA-dcSSc(OR 0.17;95%CI 0.10-0.29),肺动脉高压(PH)患病率高于两种常规亚型,10年死亡率低于ATA-dcSSc(OR 0.42;95%CI 0.2-0.85)。

要点

  • ACA-dcSSc的ILD频率高于ACA-lcSSc(OR 2.60;95%CI 1.39-4.87),但低于ATA-dcSSc(OR 0.17;95%CI 0.10-0.29)。
  • ACA-dcSSc的PH患病率高于ACA-lcSSc与ATA-dcSSc两种常规亚型。
  • ACA-dcSSc的10年死亡率低于ATA-dcSSc(OR 0.42;95%CI 0.2-0.85),5年生存率在各亚型间相当。

核心结论

  • ACA-dcSSc虽不常见,但似乎具有独特的临床表型,预后优于ATA-dcSSc。

研究设计与样本

  • 系统文献综述与随机效应荟萃分析,检索MEDLINE、Scopus和OVID(1970年1月至2023年4月),纳入6篇观察性研究、共177例ACA-dcSSc患者,研究质量采用纽卡斯尔-渥太华量表评估。

主要发现

  • ACA-dcSSc的ILD频率高于ACA-lcSSc(OR 2.60;95%CI 1.39-4.87),但低于ATA-dcSSc(OR 0.17;95%CI 0.10-0.29)。
  • ACA-dcSSc的PH患病率高于ACA-lcSSc和ATA-dcSSc两种常规亚型。
  • ACA-dcSSc的原发性心肌受累(PMI)和硬皮病肾危象(SRC)频率高于ACA-lcSSc,与ATA-dcSSc相似。
  • ACA-dcSSc的5年生存率与其他亚型相当,10年死亡率低于ATA-dcSSc(OR 0.42;95%CI 0.2-0.85)。

关键数值与推荐

  • 纳入标准为:1)成人SSc患者,可按亚型识别人口学和临床特征;2)观察性研究。
  • ACA-dcSSc vs ACA-lcSSc的ILD OR 2.60(95%CI 1.39-4.87)。
  • ACA-dcSSc vs ATA-dcSSc的ILD OR 0.17(95%CI 0.10-0.29)。
  • ACA-dcSSc vs ATA-dcSSc的10年死亡率 OR 0.42(95%CI 0.2-0.85)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anticentromere antibodies (ACA) are typically found in limited cutaneous systemic sclerosis (lcSSc), whereas patients with anti-topoisomerase I antibodies (ATA) usually exhibit diffuse cutaneous involvement (dcSSc). We aimed to investigate the clinical phenotype and outcome of ACA-dcSSc. METHODS: A systematic literature review was conducted (January 1970 to April 2023) across MEDLINE, Scopus and OVID, to define whether SSc patients (population) within the ACA-dcSSc subset (exposure) had higher/lower risk for major organ involvement (interstitial lung disease-ILD, pulmonary hypertension-PH, primary myocardial involvement-PMI, scleroderma renal crisis-SRC) and mortality (outcomes) compared to ACA-lcSSc and ATA-dcSSc. Inclusion criteria were: 1) adult SSc patients with identifiable demographic and clinical features by subtype; 2) observational studies. The quality of the studies was evaluated by the Newcastle-Ottawa Scale. Random-effects meta-analysis was performed to compare odds ratios (OR) for major organ involvement, and the 5- and 10-year mortality of ACA-dcSSc with the other subsets. RESULTS: Out of 1570 hits, six articles were included, identifying 177 ACA-dcSSc patients. In ACA-dcSSc, ILD was more frequent than in ACA-lcSSc (OR 2.60; 95 %CI 1.39-4.87) but less frequent compared to ATA-dcSSc (OR 0.17; 95 %CI 0.10-0.29). ACA-dcSSc patients had a higher prevalence of PH vs. both conventional subsets; PMI and SRC were more frequent in ACA-dcSSc compared to ACA-lcSSc, and similar to ATA-dcSSc. While 5-year survival rates were comparable among the subsets, ACA-dcSSc patients exhibited a lower 10-year mortality than ATA-dcSSc (OR 0.42; 95 %CI 0.2-0.85). CONCLUSION: Although uncommon, the ACA-dcSSc subset appears to have a distinct clinical phenotype, with a better prognosis than ATA-dcSSc.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Binda M, Ortolan A, Moccaldi B, et al. Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis. Semin Arthritis Rheum. 2024. PMID: 39657361. doi:10.1016/j.semarthrit.2024.152606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。